Infectious Disease Doctors in Old Bridge, NJ Accepting Medicare

4 Infectious Disease doctors found. Showing 1 - 4

Dr. Abha Bhargava, MD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Perrine Rd, Suite 206, Old Bridge, NJ 08857 Phone: 732-316-5100    Fax: 732-761-9179

Nasir M Ahmad, MD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Perrine Rd Ste 223, Old Bridge, NJ 08857 Phone: 732-895-1770    Fax: 732-362-7773

Dr. John R Middleton, MD Internal Medicine - Infectious Disease Medicare: Medicare Enrolled Practice Location: 3 Hospital Plz, Suite 208, Old Bridge, NJ 08857 Phone: 732-360-2700    Fax: 732-360-2703

Marilyn Baruiz-creel, M.D. Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 499 Marlboro Road, Old Bridge, NJ 08857 Phone: 732-360-1910    Fax: 732-360-9700

News Archive

Acupuncture treatment lowers frequency of hotflashes for 50% of women, study finds

Hot flashes - the bane of existence for many women during menopause - can be reduced in frequency by almost half for about 50 percent of women over eight weeks of acupuncture treatment, according to scientists at Wake Forest Baptist Medical Center.

Infecting mosquitoes with Wolbachia bacteria increases their resistance to human disease-causing viruses

Earlier this year, researchers showed that they could cut the lives of disease-carrying mosquitoes in half by infecting them with a bacterium they took from fruit flies. Now, a new report in the December 24th issue of Cell, a Cell Press publication, suggests that their strategy might do one better: The Wolbachia bacteria also makes the mosquitoes more resistant to infection by viruses that are a growing threat to humans, including those responsible for dengue fever and Chikungunya.

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Celgene International Sarl today announced a collaboration to conduct an international randomized study to evaluate the therapeutic potential of the REVLIMID/rituximab combination regimen (R2) in patients with newly diagnosed follicular lymphoma.

Takeda signs agreement to acquire Multilab

Takeda Pharmaceutical Company Limited and Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda. today jointly announced that both parties have signed an agreement whereby Takeda Farmacêutica Brasil Ltda., a wholly-owned subsidiary of Takeda, aims to acquire Multilab.

Read more Medical News

› Verified 1 days ago